Merck KGaA (OTCMKTS:MKGAF – Get Free Report) saw unusually-high trading volume on Tuesday. 5,085 shares changed hands during mid-day trading, an increase of 712% from the previous session’s volume of 626 shares. The stock last traded at $162.30 and had previously closed at $155.45.
Merck KGaA Stock Down 3.0%
The company has a market capitalization of $20.44 billion, a PE ratio of 24.14 and a beta of 0.96. The firm’s 50-day simple moving average is $160.93 and its 200 day simple moving average is $152.05. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.84 and a current ratio of 1.31.
Institutional Trading of Merck KGaA
A number of institutional investors have recently added to or reduced their stakes in the stock. Puzo Michael J purchased a new position in Merck KGaA in the second quarter valued at about $2,230,000. MASTERINVEST Kapitalanlage GmbH purchased a new stake in shares of Merck KGaA during the 2nd quarter worth approximately $4,896,000. Ames National Corp purchased a new stake in shares of Merck KGaA during the 2nd quarter worth approximately $1,009,000. Notis McConarty Edward acquired a new stake in shares of Merck KGaA in the 2nd quarter worth approximately $1,304,000. Finally, North Star Asset Management Inc. purchased a new position in Merck KGaA in the 2nd quarter valued at approximately $1,411,000. Hedge funds and other institutional investors own 0.10% of the company’s stock.
About Merck KGaA
Merck KGaA is a Germany-based science and technology company headquartered in Darmstadt. Founded in 1668, it is one of the world’s oldest operating pharmaceutical and chemical companies. Merck KGaA is separate from the U.S.-based Merck & Co, Inc, although the two companies share historical roots.
The company operates through three business sectors: Life Science, Healthcare and Electronics. Its Life Science business supplies laboratory products, research tools, chemicals and bioprocessing technologies used by pharmaceutical, biotechnology and academic customers.
Featured Stories
- Five stocks we like better than Merck KGaA
- Constellation Brands Beat Earnings, But Beer Demand Is Still a Problem
- Tesla’s EV Delivery Beat Is In, So What Happens Now?
- Skydance Just Became a Media Giant—With an $80 Billion Debt Load
- Could Velo3D Be the Next Defense Buyout Target?
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
